AbbVie is expected to report Q1 2026 revenue of $14.78 billion and adjusted EPS of $2.69, with the stock currently trading at $198.71 against an average analyst price target of $253.50.
The primary focus for investors remains the sales performance of next-generation immunology leaders Skyrizi and Rinvoq, which are projected to generate a combined $6.50 billion this quarter.
Analysts are specifically monitoring Skyrizi's dominance in the frontline Crohn’s disease market and any updates to full-year 2026 guidance following recent acquired research charges. Steady growth in the neuroscience and aesthetics portfolios is expected to provide further evidence of AbbVie’s successful transition beyond the Humira patent cliff.